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noninvasive tumor detection in mice
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Abstract: Receptor targeting is an effective method of enhancing fluorescence signal in tumors for optical imaging. We previously used epidermal growth factor (EGF) conjugated to IRDye 800CW to detect and track orthotopic prostate tumors in mice. In
this study, our goal was to identify a reliable assay for targeting agent integrity in vitro that correlated with signal strength in vivo.
Binding of IRDye 800CW EGF to intact A431 human epidermoid carcinoma cells was quantified in a microplate assay. Specificity was confirmed by competition with unlabeled EGF or monoclonal antibody blocking. Biological activity of intact and damaged targeting agents relative to unlabeled EGF was determined by binding and stimulation of extracellular signal-regulated kinase (ERK) phosphorylation. Both assays indicated a reduction of up to 60% of the fluorescence intensity with damaged agents.
Using a research prototype imaging system optimized for IRDye 800CW detection, we compared the efficacy of intact and damaged targeting agents for imaging subcutaneous tumors in mice. In live animal images and in sections of the excised tumors, damaged targeting agents consistently yielded diminished fluorescence signals corresponding to the reduction observed in microplate
assays. This is the first study to directly correlate targeting agent signal strength in whole cell binding, In-Cell Western, and in
vivo near-infrared imaging.
Keywords: EGF receptor, IRDye 800CW EGF, In-Cell Western assay, Binding affinity, Noninvasive, Whole animal imaging
Abbreviations: NIR, near-infrared; RGD, Arg-Gly-Asp; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; ATCC, American Type Culture Collection; DMEM, Dulbecco’s modified Eagle’s medium; MEM, minimal essential medium; PBS, phosphate-buffered saline; FPLC, fast protein liquid chromatography; TEAA, triethylammonium acetate; CCD,
charge-coupled device; SNR, signal-to-noise ratio; ROI, region of interest; FITC, fluorescein isothiocyanate.

and [4]. Although both tumor detection methods are powerful and sensitive, their major limitation is a requirement for
specific cell lines. An alternative approach is the exploitation
of high-affinity receptor–ligand interactions to target molecular features of the tumor cell with coupled fluorophores.
Targeting agents that have been used successfully for optical noninvasive detection of tumor xenografts in mice include monoclonal antibodies [5] and [6], small polypeptide
growth factors [7] and [8], and peptide analogues of extracellular ligands such as endostatin [9] and somatostatin [10].
The most effective coupled fluorophores are those with fluorescence emission maxima in the near-infrared (NIR) range

Studies of tumor growth and metastasis in small animal
models have benefited greatly from the expanded availability of optical imaging techniques that specifically detect tumor tissue in live animals [1] and [2]. A major advantage of
optical imaging is the cost-effective accessibility of the requisite instrumentation. Several promising methods use molecular approaches to enhance the specificity of optical detection. Frequently, chosen techniques include measurement
of bioluminescence, in which tumor cell lines bearing a luciferase reporter gene are detected by systemic delivery of a
luminescent substrate, and gene-encoded fluorescence of tumor cell lines expressing green or red fluorescent proteins [3]
47
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of 780 to 850 nm. Due to low-absorbance spectra of bodily
fluids and tissues, imaging in the NIR offers the advantages
of relatively deep tissue penetration and low autofluorescence [11] and [12]. Examples include targeting of the integrin αvβ3 using variations of Arg-Gly-Asp (RGD) peptides
linked to Cy5.5 [13], [14], [15], and [16], Alexa Fluor 680
[13], and IRDye 800CW [16]. Recently, epidermal growth
factor (EGF) labeled with Cy5.5 was used to quantify therapeutic efficacy of anti-EGF receptor antibodies for treating
mammary carcinoma in mice [8].
To optimize receptor-targeted signal strength in NIR
optical imaging, a detailed understanding of the targeting
mechanism and fluorophore function is critical. The EGF
receptor is a potential biomarker for numerous preclinical models of human cancer because its expression is elevated an order of magnitude or more relative to normal
cells in cancers of the breast [17], prostate [18], lung [19],
ovary [20], and brain [21]. Furthermore, its signaling functions are well characterized and accessible to convenient
high-throughput in vitro validation assays to ensure that
bioactivity of the ligand is maintained despite chemical
coupling. For example, EGF binds to a cell surface transmembrane receptor tyrosine kinase, and this induces dimerization of the receptors, triggering a phosphorylation
cascade through numerous extracellular-regulated kinases
[22]. Because antibodies are available to specifically quantify the phosphorylated form of several kinases, activity of
EGF may be verified directly by receptor binding and indirectly by stimulated kinase activity.
We previously conjugated IRDye 800CW to EGF to
track longitudinal growth of orthotopic prostate tumors in
mice [23] and found that the conjugate was a sensitive tumor targeting agent with excellent tissue penetration. We
hypothesized that an aspect of the normal function of EGF
contributing to the strong signal obtained from this agent
could be receptor-mediated endocytosis of the ligand–receptor complex. This would imply that initial high-affinity binding of the targeting agent is essential for maximal
fluorescence signal strength in animals. Thus, animal numbers could be minimized in imaging experiments if suboptimal conjugate binding in vitro was found to correlate with
reduced tumor targeting efficacy in vivo. Furthermore, it
would be very powerful to have a straightforward in vitro
assay that could directly predict relative efficiencies of two
different drugs or ligands with the same in vivo target. In
this study, we used IRDye 800CW EGF to target A431 human epidermoid carcinoma cells in vitro and in vivo. Specifically, we compared whole cell binding, extracellular
signal-regulated kinase (ERK) phosphorylation, and subcutaneous tumor targeting of optimal and damaged conjugates. Our characterization confirms that poor quality of a
receptor targeting agent can be detected by measuring in vitro binding equilibria and that reduced bioactivity is detrimental to imaging sensitivity.
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Materials and methods
Cell culture, materials, and reagents
A431 human epithelial squamous carcinoma cells were purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum. PC3M-LN4 human prostate adenocarcinoma
cells were kindly provided by Isaiah J. Fidler (M.D. Anderson Cancer Center, Houston, TX, USA) and maintained in
minimal essential medium (MEM) containing 10% fetal bovine serum, sodium pyruvate, and nonessential amino acids. A purified mouse diet (AIN-93M) was obtained from
Harlan Teklad (Madison, WI, USA). Monoclonal antibody
C225 (Cetuximab, ImClone Systems) was graciously provided by Chun Li (M. D. Anderson Cancer Center). TOPRO-3 was obtained from Molecular Probes (Eugene, OR,
USA). Antibodies specific for β-tubulin (H-235) and pERK (E-4) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The IRDye 800CW EGF targeting
agent, as well as the Odyssey Infrared Imaging and Aerius
Automated Infrared Imaging Systems, were provided by LICOR Biosciences (Lincoln, NE, USA).
Characterization of IRDye 800CW EGF binding specificity
in vitro
The binding specificity of the IRDye 800CW EGF compound was evaluated on A431 and PC3M-LN4 cells by
an In-Cell Western assay [23] and [24]. Briefly, cells were
grown to approximately 90% confluency in a microtiter plate (Nunc, Roberts, WI, USA) and starved for 2 h
in serum-free media. For binding assays, starvation media were replaced with media containing increasing concentrations of IRDye 800CW only (0.002–3.3 μM) or
IRDye 800CW EGF (0.01–70 nM). Specificity of the labeled compound was evaluated by competition assays in
which starvation media were replaced with media containing unlabeled EGF (in increasing concentrations from 0.01
to 2.14 μM) + IRDye 800CW EGF (70 nM) or C225 (0.5–
200 μg/ml) + IRDye 800CW EGF (70 nM). Cells were incubated at room temperature (25 °C) for 2 min and fixed
with 4% formaldehyde solution for 20 min. Four washes
in 1 × phosphate-buffered saline (PBS) + 0.1% Triton X100 were done to remove unbound dye and permeabilize the cells. The plates were blocked in Odyssey Blocking Buffer for 1.5 h and then incubated with TO-PRO-3
(1:5000) for normalization of cell number using the 700nm channel. Washing steps were repeated, and the plate
was scanned on Aerius. Quantifications were normalized
by ratiometric analysis of the 700-nm values applied to the
800-nm values.
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Preparation of targeting agents
High-quality targeting agents were prepared by standard fast
protein liquid chromatography (FPLC) methods. All separations were performed on an Agilent 1100 series HPLC system (Agilent Technologies, Santa Clara, CA, USA). Sample detection employed a diode array detector set at 260 and
780 nm, and purifications were carried out at 5 °C. Standard FPLC conditions were achieved with this instrument
using an isocratic method suitable for size exclusion chromatography. Following conjugation, the coupling mixture was applied to a 35 × 250-mm Omnifit column (Western Analytical Products, Wildomar, CA, USA) packed with
Superdex 30 gel filtration media (GE Healthcare/Amersham Biosciences, Piscataway, NJ, USA). This column was
equilibrated and eluted at 0.5 ml/min (6 bar pressure) with
isocratic 1 × PBS (pH 7.4). The eluted material was filter
sterilized by passage through a 0.2-μm syringe filter into a
sterile container. Absorbance at 280 nm was used to calculate EGF concentration from the published molar extinction
coefficient. Dual wavelength absorbances were used to determine the dye/protein ratio, which was maintained consistently across all coupling reactions. Dual wavelength absorbance traces from size exclusion chromatography were also
used to determine the relative amounts of coupled and unreacted dye in all preparations.
Poor-quality targeting agents were prepared by subjecting unlabeled EGF or IRDye 800CW EGF to HPLC purification, which is detrimental to protein activity because
of the harsh denaturing solvent conditions [25]. A reversephase C18 Zorbax column (250 × 9.6 mm, 300 Å pore size,
5 μm particle size) was used. Solvents included aqueous 50
mM triethylammonium acetate (TEAA, pH 5.9) (A) and
acetonitrile (B) in a gradient of 20% B to 31% B in 15 min.
The purification was performed at a flow rate of 4.7 ml/
min (100 bar pressure). Sample was protected from light,
dried overnight under vacuum, reconstituted in 1 × PBS,
and applied to a cation (Na+ resin) exchange column equilibrated with 1 × PBS. Following elution from the column
with 1 × PBS, the sample was lyophilized. Protein concentration, dye/protein ratio, and unreacted dye quantity were
measured as above.
Quantification of downstream signaling by IRDye 800CW
EGF
The ability of the targeting agent to stimulate ERK phosphorylation in A431 cells was compared with that of unlabeled EGF. Cells at 90% confluence in a 96-well plate were
serum starved for 2 h. Starvation media were replaced with
stimulation media containing 0.03 to 14 nM IRDye 800CW
EGF (FPLC), IRDye 800CW EGF (HPLC), unlabeled EGF
(FPLC), or unlabeled EGF (HPLC). Cells were incubated
for 2 min at room temperature followed by fixation and per-
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meabilization as above. An initial scan on Aerius was done
to obtain the level of signal from the conjugated EGF bound
to receptors. Then plates were blocked for 1.5 h in Odyssey
Blocking Buffer followed by incubation with anti-β-tubulin (1:100) and anti-p-ERK (1:100) for 1.5 h at room temperature. Plates were washed four times in 1 × PBS + 0.1%
Tween 20 prior to incubation with IRDye 800CW goat antirabbit (1:800) and IRDye 680 goat anti-mouse (1:200) antibody conjugates for 1 h. Cells were washed again, and the
plate was scanned on the Aerius. The final ratiometric analysis was adjusted for the initial binding signal, and p-ERK
signal was normalized to β-tubulin.
Subcutaneous injections
Male NOD/SCID mice (Jackson Laboratory, Bar Harbor,
ME, USA) and athymic Nu/Nu mice (Charles River, Wilmington, MA, USA) used in these experiments were maintained under the supervision and guidelines of the University of Nebraska–Lincoln Institutional Animal Care and Use
Committee. PC3M-LN4 cells were trypsinized, washed, and
resuspended at 5 × 106 cells/ml in serum-free MEM [26].
Each NOD/SCID mouse was injected subcutaneously in the
flank with 100 μl of cell suspension (0.5 × 106 cells) using a
1-ml insulin syringe. Tumors reached approximately 0.5 cm
in size at 4 weeks. A431 cells were trypsinized, washed, and
resuspended at 2 × 107 cells/ml in serum-free medium for
subcutaneous injections in the flank (2 × 106 cells) of male
athymic Nu/Nu mice. Animals were carried for approximately 2 weeks until tumors reached roughly 0.5 cm in size.
In vivo imaging of IRDye 800CW EGF
NIR fluorescence imaging in live animals was performed
with a research prototype LI-COR Biosciences small animal imager. The LI-COR instrument is a light tight chamber
equipped with a cooled charge-coupled device (CCD) camera, area illumination via diode lasers, and a selection of excitation and detection optical fluorescent filters tuned specifically for IRDye 800CW. Images were acquired and analyzed
with Wasabi software (Hamamatsu Photonics, Hamamatsu
City, Japan) or Adobe Photoshop (Adobe Systems, San Jose,
CA, USA). NOD/SCID mice were shaved prior to image
collection. All mice were anesthetized with 2% isoflurane
throughout procedures.
To establish initial conditions, IRDye 800CW EGF
(1 nmol) was injected via the tail vein into a tumor-negative
mouse of each strain and evaluated for systemic clearance by
NIR imaging at intervals of 1 to 24 h over a period of 3 days,
after which time more than 90% of the signal had cleared.
Then mice bearing subcutaneous PC3M-LN4 or A431 tumors (diameter ~0.5 cm) were injected with IRDye 800CW
EGF (1 nmol) and evaluated for tumor-specific retention of
the agent by NIR imaging at 24-h intervals for up to 8 days.
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Signal-to-noise ratios (SNRs) calculated as described below
were used to determine an optimal time point of 72 to 96 h
for imaging tumors. Subsequently, an additional eight athymic mice with A431 tumors were injected to compare signal
strength of the targeting agents prepared by different methods. One mouse was injected with 0.9% saline, one mouse
received unconjugated IRDye 800CW, two mice were given
IRDye 800CW EGF (1 nmol) from sources A and B purified
by FPLC, and four mice were injected with HPLC-damaged
IRDye 800CW EGF (1 nmol) purified by HPLC. Animals
were imaged 3 days postinjection and euthanized. Tumors
were excised, weighed, measured, and paraffin embedded
for section scan analysis on Odyssey.
Statistical analysis
Images for each mouse were normalized using the same intensity scale with a common minimum and maximum value.
SNR was calculated using the following formula:

Regions of interest (ROIs) with identical areas were used
for both tumor and background. ROIs were quantified for total pixel and mean pixel values. The standard deviation of
mean backgrounds was calculated using three to five ROIs.
This calculation yields the number of standard deviations
over background represented by the suspect tumor/signal.
Due to tumor size differences between the animals receiving
quality targeting agents, tumor signal minus background signal of similar-size ROI was then corrected for area (pixels).
The percentage difference from FPLC-purified agent was
determined for HPLC-purified agents.
Tissue section analysis
After final imaging (day 3 or 4 postinjection), animals were
sacrificed. Tumors were excised, scanned on Odyssey,
weighed, measured, and preserved in Z-fix (Anatech, Battle
Creek, MI, USA), followed by paraffin embedding and tissue
sectioning. Sections (5 μm thickness) were scanned in both
the 700-nm channel, for tissue autofluorescence, and the 800nm channel, for the targeted IRDye 800CW EGF fluorescence signal using Odyssey. The area-weighted fluorescence
signal from the 800-nm channel was used to compare targeting agent specificities among experimental conditions.
Results and discussion
In vitro specificity of IRDye 800CW EGF for tumor cell
lines
Effective use of whole animal NIR optical imaging for sensitive detection of tumor tissue requires highly specific biomarkers that can be labeled to illuminate tumor cells within
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live mice. Maximal emission of IRDye 800CW is 789 nm,
so it falls in an optimal region of the spectrum to obtain superior signal strength. We previously coupled EGF to IRDye
800CW and found this targeting agent to be highly sensitive and specific due to its strong signal [23]. Our goal in the
current study was to determine an aspect of EGF biological
function quantifiable in vitro that reflects maximal tumor targeting potential.
We first characterized binding of the targeting agent to
A431 cells by a microplate NIR fluorescence assay as we
had done previously for PC3M-LN4 human prostate tumor
cells [23]. Confluent monolayer cultures of A431 cells were
established in 96-well plates and treated with increasing
concentrations of IRDye 800CW EGF to establish a dose–
response curve for binding of the targeting agent to EGF receptors on the cells. Fluorescence signal became significant
at 1 nM concentrations and increased exponentially in a concentration-dependent fashion (Figure 1A). To verify receptor targeting, we performed the same measurements with
unconjugated dye, showing negligible increases in fluorescence over a similar concentration course (Figure 1A, circles). The specificity of the conjugate for the EGF receptor
on the cells was evaluated by competitions with unlabeled
EGF (Figure 1B) and with C225, a monoclonal antibody that
blocks ligand binding by the EGF receptor [27] (Figure 1C).
Unlabeled EGF reduced fluorescence in a concentration-dependent manner with an IC50 of approximately 0.1 μM. The
antibody competition was also dose dependent with an IC50
of approximately 10 μg/ml. These results are comparable to
those obtained with prostate tumor cells. Importantly, saturation of binding to whole cells occurred above 0.1 μM. The
value was approximately 0.16 μM for PC3M-LN4 cells,
showing a half-maximal binding constant of approximately
70 to 80 nM, in good agreement with the inhibition constant
for unlabeled EGF. Thus, coupling of EGF to the fluorophore
did not affect receptor affinity.
To confirm that bioactivity of the targeting agent was indicated accurately by binding affinity, we used an In-Cell
Western assay that was developed previously for the quantification of kinase phosphorylation in whole cells [24]. No
significant decrease in ERK phosphorylation was noted between cells treated with equimolar concentrations of unlabeled EGF and IRDye 800CW EGF (data not shown). This
is consistent with results from other investigators who have
shown that both fluorescein isothiocyanate (FITC)–EGF [7]
and fluorescent quantum dot–EGF [28] conjugates are effectively internalized by ligand-induced endocytosis of the
bound EGF receptor complex, also a downstream effect of
biologically intact EGF.
Impairment of binding of EGF and EGF-stimulated ERK
phosphorylation by HPLC purification
We next evaluated whether the microplate binding and
In-Cell Western assays could effectively distinguish between
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Figure 2. Biological activity elicited by labeled EGF. EGF from
four sources (denoted as A, B, C, and D) was conjugated to IRDye
800CW and purified by HPLC. A431 cells at 90% confluence in 96well plates were stimulated with the indicated concentrations of the
respective agents or with the maximally active FPLC-purified conjugates corresponding to sources A and B. The plate was scanned to
quantify binding of the IRDye 800CW EGF targeting agents (A).
The extent of ERK phosphorylation stimulated in each condition was
assessed in the same plate by the In-Cell Western assay using antibodies to total ERK and p-ERK (B). The mean ± SD for three replicate wells is plotted.

Figure 1. In vitro binding specificity of IRDye 800CW EGF for tumor cells in culture. A431 cells cultured to 90% confluence in 96well plates were incubated with increasing concentrations of IRDye
800CW EGF (diamonds) or unconjugated nonreactive IRDye 800CW
(circles) for 2 min and then washed, fixed, permeabilized, and stained
with TO-PRO-3 (A). For competitions, cells were incubated with a
fixed concentration of IRDye 800CW EGF (70 nM) containing the
indicated concentrations of unlabeled EGF (B) or C225, an EGF receptor blocking antibody (C). All plates were scanned at two wavelengths on the Aerius near-infrared scanner. The 800-nm signal, normalized to the 700-nm control, is plotted as the means ± SD of three
replicate wells.

ligands with differential binding affinities. To obtain low-affinity ligands for comparisons, we conjugated IRDye 800CW
to EGF from four independent commercial sources and subjected each conjugate to HPLC purification. Binding of these
four targeting agents (denoted A, B, C, and D in Figure 2) to
A431 cells was compared by NIR fluorescence intensity to
the binding of standard maximally active FPLC-purified conjugate from sources A and B. All four preparations demonstrated significant reductions in binding (up to 60%) at all concentrations (Figure 2A). Thus, the damage inflicted on EGF

by HPLC treatment dramatically affected its cell binding potential. When we assayed p-ERK levels using the four targeting agents compared with unlabeled (data not shown) or
conjugated EGF from sources A and B (Figure 2B), the best
performance of any HPLC-purified compound was 28% of
unlabeled EGF stimulation. Reduced levels of ERK phosphorylation confirmed compromised function of the HPLCtreated targeting agents.
Kinetics of IRDye 800CW EGF clearance in vivo
Ultimately, our goal was to determine whether impaired
function of the EGF receptor targeting agent in vitro would
correlate with poor tumor targeting in mice. We first determined clearance kinetics of the targeting agent in normal
and tumor-bearing mice. Clearance was monitored by injecting animals with 1 nmol of FPLC-purified IRDye 800CW
EGF via the tail vein and collecting NIR images over time
from 15 min to 24 h (Figure 3A). The pseudo-colored images depict the color-enhanced fluorescence intensity superimposed on white light images of a representative mouse.
Fluorescence intensity in regions of interest encompassing
the whole animal (large ROI) or limited to the abdominal
area (small ROI) was quantified to evaluate clearance. We
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Figure 3. Clearance kinetics of IRDye 800CW EGF from normal and tumor-bearing mice. (A) IRDye 800CW EGF (1 nmol) was injected intravenously into a normal NOD/SCID mouse. Images were collected prior to injection (0 h) and at the indicated times postinjection. Results are
shown as color-enhanced fluorescence intensity superimposed on the white light images in the ventral view. Signal intensities (at 789 nm) were
normalized to background fluorescence and plotted using the whole animal (large ROI, dark bars) or an arbitrary abdominal ellipse (small ROI,
light bars) as ROIs. (B) IRDye 800CW EGF was injected intravenously into mice with subcutaneous PC3M-LN4 prostate tumor xenografts,
and images were collected at the indicated times postinjection. SNR was calculated using a single elliptical ROI denoted on the tumor in blue
and four background ellipses (orange) placed arbitrarily in irrelevant adjacent sites on the flank as shown. Fluorescence is also present in the
kidneys in these dorsal views. Calculated SNR was plotted to obtain an optimal imaging time point for subsequent experiments.

observed an initial increase in whole animal fluorescence intensity for the first 3 to 4 h as the targeting agent circulated
to the capillaries of the skin. Subsequently, the signal was
seen to pass through the liver, intestines, kidneys, and bladder. The analysis confirmed that 75% of the signal cleared
after 8 h and that more than 90% cleared after 24 h.
Then we monitored a similar time course for clearance of
the targeting agent from tumor-positive animals (Figure 3B).
Mice bearing subcutaneous tumors of approximately 0.5 cm
in diameter (measured by digital calipers) were injected as
above with IRDye 800CW EGF, imaged immediately, and
imaged repeatedly at 24-h intervals. As observed for the tu-

mor-negative controls, whole animal and abdominal signal
intensity peaked at 3 to 4 h but had diminished by more than
90% within 24 h (data not shown). Analysis of SNR comparing mean fluorescence intensity in an arbitrarily chosen ROI
within the tumor, designated as a blue ellipse, to the mean of
four background areas of identical size, shown as orange ellipses, exhibited an initial time-dependent increase. Eventual
saturation of SNR indicated that the time of maximal sensitivity for imaging was 72 to 96 h, and subsequent images were
collected at 72 h (Figure 3B). In vivo, IRDye 800CW EGF
fluorescence following systemic clearance was amplified in
the tumors relative to the whole animals and was also specific,
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Table 1. Summary of tumor imaging results

a

Figure 4. Targeting agent quality analysis in vivo. Male athymic Nu/
Nu mice bearing A431 subcutaneous tumors (~0.5 cm diameter) were
injected intravenously with IRDye 800CW EGF (1 nmol) purified by
FPLC (A and C) or HPLC (B and D). Panels A and B illustrate use
of the conjugate to EGF from source A in Figure 3, and for panels C
and D source B was used. Images were collected on anesthetized animals at 72 h postinjection. Tumors were excised, fixed, paraffin embedded, and sectioned for fluorescence signal determination by twocolor scanning on the Odyssey (inset panels).

as shown by antibody blocking. The sensitivity of this fluorescence signal lends support to the choice of EGF receptor
as an epithelial or prostate tumor target and demonstrates that
IRDye 800CW is an effective labeling fluorophore.
Subcutaneous tumor targeting by IRDye 800CW EGF
To optimize targeting and tumor-specific signal accumulation in noninvasive imaging, it is important to understand
the functional parameters of the biomarker and its response
to the target. Using the In-Cell Western assay, we detected
impaired binding and response of the EGF receptor signaling cascade when the EGF conjugate was subjected to
HPLC treatment. We performed an animal imaging study to
determine whether impaired binding function would translate to poor tumor signal. FPLC- or HPLC-purified IRDye
800CW EGF from two sources (A and B) was injected via
the tail vein into athymic mice bearing approximately 0.5cm subcutaneous A431 tumors. Mice were imaged 3 days
postinjection (Figure 4). The arrowheads in Figure 4 indicate positions of detected tumor tissue in these representative fluorescence images, which have been corrected for
background. Figs. 4A and C illustrate signal intensity in animals injected with the FPLC-purified targeting agent, and
Figs. 4B and D show the effect of the corresponding HPLC
form. These images were analyzed to determine total fluorescence in the tumor (Table 1). Mice receiving HPLC-purified targeting agents from the two different preparations had
approximately 28 and 64% lower signal compared with mice
injected with minimally damaged agents (Table 1). Similar
results were obtained when damaged agents were injected
in mice bearing 22Rv1 prostate tumors, confirming that this

Normalized fluorescence for intact animals: mean pixel fluorescence (tumor)
minus mean pixel fluorescence (background).
b 800 nm fluorescence per area (mm2).
c Comparison with source A FPLC to determine percentage loss.
d Comparison with source B FPLC to determine percentage loss (numbers in
parentheses).

phenomenon is not unique to the A431 cells. In images not
shown, additional mice were injected with HPLC-purified
probes from sources C and D, but the fluorescence signal
from these animals was diminished 80 to 90% with respect
to that calculated for the animals receiving optimized preparations (Table 1). Thus, the magnitude of the differences varied considerably, but a targeting agent exhibiting suboptimal
signaling potential in vitro correlated strongly with poor signal strength in live animal imaging.
Finally, tumors were excised and sectioned for fluorescence scanning analysis to verify whether signal intensity
measured in the animal was attributable to fluorescence in the
tumor tissue and whether the intensity was consistent throughout the tumor. Sections were scanned on the Odyssey in two
channels, and the corresponding merged images are shown as
insets in Figure 4. Red represents tissue autofluorescence in
the 700-nm channel, and green denotes specific fluorescence
in the 800-nm channel resulting from IRDye 800CW EGF.
Normalized fluorescence of the tissue sections is presented in
Table 1. Signal intensity was evident throughout the tumors
irrespective of targeting agent. Consistent with results from
intact animal image analysis, sections exhibited signal reductions of approximately 25 to 60%. Thus, performance of targeting agents damaged by HPLC purification, as identified in
vitro by the assay for ERK phosphorylation, again translated
to poor outcomes in whole animal imaging experiments.
In conclusion, we have characterized an effective targeting agent for noninvasive optical detection and tracking of
tumors in mice. The fluorophore used, IRDye 800CW, can
be easily coupled to many ligand or targeting molecules of
interest. We have found that an in vitro assay that detects
binding and efficacy of EGF-conjugated products in stimulating downstream biological function is an accurate estimate of targeting efficacy in vivo. We expect this application to have further value in probe and drug development as
a correlate assay for other biolabels to estimate competitive
ligand and/or drug interactions in vivo.
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